Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18507
Country/Region: Kenya
Year: 2017
Main Partner: Centre for Health Solutions
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $4,014,012 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: TB/HIV (HVTB) $169,516
Testing: HIV Testing and Counseling (HVCT) $1,440,424
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $375,870
Treatment: Adult Treatment (HTXS) $1,824,790
Treatment: Pediatric Treatment (PDTX) $203,412
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2018 357
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2018 4,575
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2018 893
GEND_GBV Number of people receiving post-GBV care 2018 5,468
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 522,696
HTS_TST Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative 2018 32,111
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative 2018 9,687
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative 2018 4,845
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative 2018 305,197
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative 2018 164,711
HTS_TST Sum of Test Result disaggregates 2018 6,087
HTS_TST_POS By Test Result: Positive 2018 6,087
HTS_TST_POS Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive 2018 929
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive 2018 103
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive 2018 48
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive 2018 3,307
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive 2018 1,782
PMTCT_ART Already on ART at beginning of current pregnancy 2018 534
PMTCT_ART New on ART 2018 312
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2018 846
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 33,529
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2018 846
PMTCT_EID Number of infants with a negative virological test result between 2 and 12 months of birth 2018 246
PMTCT_EID Number of infants with a negative virological test result within 2 months of birth 2018 588
PMTCT_EID Number of infants with a positive virological test result between 2 and 12 months of birth 2018 6
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2018 6
PMTCT_STAT By Age (Numerator): 10-14 2018 31
PMTCT_STAT By Age (Numerator): 15-19 2018 3,482
PMTCT_STAT By Age (Numerator): 20-24 2018 10,836
PMTCT_STAT By Age (Numerator): 25-49 2018 19,151
PMTCT_STAT By Age (Numerator): 50+ 2018 14
PMTCT_STAT By Age (Numerator): Unknown Age 2018 12
PMTCT_STAT By Number of known positives: 10-14 2018 2
PMTCT_STAT By Number of known positives: 15-19 2018 16
PMTCT_STAT By Number of known positives: 20-24 2018 104
PMTCT_STAT By Number of known positives: 25-49 2018 433
PMTCT_STAT By Number of known positives: Unknown Age 2018 2
PMTCT_STAT By Number of new negative: 10-14 2018 29
PMTCT_STAT By Number of new negative: 15-19 2018 3,451
PMTCT_STAT By Number of new negative: 20-24 2018 10,668
PMTCT_STAT By Number of new negative: 25-49 2018 18,479
PMTCT_STAT By Number of new negative: 50+ 2018 14
PMTCT_STAT By Number of new negative: Unknown Age 2018 77
PMTCT_STAT By Number of new positives: 15-19 2018 16
PMTCT_STAT By Number of new positives: 20-24 2018 102
PMTCT_STAT By Number of new positives: 25-49 2018 230
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 33,529
PMTCT_STAT_den By Age (Denominator): <15-19 2018 3,481
PMTCT_STAT_den By Age (Denominator): 10-14 2018 31
PMTCT_STAT_den By Age (Denominator): 20-24 2018 10,841
PMTCT_STAT_den By Age (Denominator): 25-49 2018 19,162
PMTCT_STAT_den By Age (Denominator): 50+ 2018 12
PMTCT_STAT_den By Age (Denominator): Unknown Age 2018 11
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 11
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 259
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 6
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 338
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2018 614
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 614
TB_ART_den Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 11
TB_ART_den Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 260
TB_ART_den Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 6
TB_ART_den Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 337
TB_PREV By Age/Sex (Numerator): <15, Female 2018 103
TB_PREV By Age/Sex (Numerator): <15, Male 2018 70
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 3,285
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 1,780
TB_PREV By Therapy type (Numerator): 6-12 Month IPT 2018 6,232
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 5,232
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 5,746
TB_PREV_den By Age/Sex (Denominator): <15, Female 2018 108
TB_PREV_den By Age/Sex (Denominator): <15, Male 2018 70
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 3,618
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 1,950
TB_PREV_den By Therapy type (Denominator): 6-12 Month IPT 2018 5,746
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 73
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 687
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 69
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 1,378
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2018 2,207
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2018 2,262
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 86
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 703
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 68
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 1,405
TX_CURR Age/Sex: <1 2018 41
TX_CURR Age/Sex: <1-9 2018 592
TX_CURR Age/Sex: 10-14 Female 2018 517
TX_CURR Age/Sex: 10-14 Male 2018 487
TX_CURR Age/Sex: 15-19 Female 2018 523
TX_CURR Age/Sex: 15-19 Male 2018 739
TX_CURR Age/Sex: 20-24 Female 2018 695
TX_CURR Age/Sex: 20-24 Male 2018 429
TX_CURR Age/Sex: 25-49 Female 2018 12,009
TX_CURR Age/Sex: 25-49 Male 2018 4,360
TX_CURR Age/Sex: 50+ Female 2018 3,908
TX_CURR Age/Sex: 50+ Male 2018 2,522
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 26,822
TX_CURR Sum of age/sex disaggregates 2018 1,262
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2018 85
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2018 94
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2018 2,900
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2018 2,649
TX_NEW Breastfeeding status 2018 7
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 5,728
TX_NEW Pregnancy status 2018 20
TX_NEW Sum of Aggregated Age/Sex disaggregates 2018 5,728
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 26,815
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 23,962
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 613
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 36
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 611
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 39
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 14,749
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 1,106
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 6,312
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 496
TX_PVLS Numerator: Indication: Routine 2018 22,284
TX_PVLS Numerator: Indication: Targeted 2018 1,678
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 759
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 62
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 759
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 52
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 16,118
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 1,229
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 7,276
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 534
TX_PVLS_den Denominator: Indication: Routine 2018 24,942
TX_PVLS_den Denominator: Indication: Targeted 2018 1,884
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 78
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 76
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 3,250
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 1,496
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 4,900
TX_RET Numerator by Status: Breastfeeding 2018 12
TX_RET Numerator by Status: Pregnant 2018 553
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 5,442
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 86
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 84
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 3,612
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 1,660
TX_RET_den Denominator by Status: Breastfeeding 2018 12
TX_RET_den Denominator by Status: Pregnant 2018 616
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 26,824
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 347
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2018 6
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2018 1
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 173
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 167
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 972
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 940
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2018 16,484
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2018 8,428
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2018 4,284
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2018 255
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2018 823
TX_TB_den Denominator: By Screen Result: Negative 2018 21,451
TX_TB_den Denominator: By Screen Result: Positive 2018 5,362
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2018 5,362
Cross Cutting Budget Categories and Known Amounts Total: $193,200
Gender: Gender Based Violence (GBV) $128,000
GBV Prevention
Implementation
Capacity building
Post GBV Care
Implementation
Capacity building
Motor Vehicles: Purchased $65,200